Sigurd D. Süßmuth

Boehringer Ingelheim (Germany) — Germany

Neuroscience · Life Sciences

32h-index2.9kcitations81works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Neurodegenerative Diseases(27), Neurological disorders and treatments(15), Amyotrophic Lateral Sclerosis Research(12), Parkinson's Disease Mechanisms and Treatments(11), Alzheimer's disease research and treatments(9)

Publications78 total

Autorinnen und Autoren
Elsevier eBooks·2025
Efficacy, Tolerability, and Safety of TRPC4/5 Inhibitor BI 1358894 in Patients With Major Depressive Disorder and Inadequate Response to Antidepressants
The Journal of Clinical Psychiatry·2025
Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder
Clinical Pharmacology & Therapeutics·2025Open Access
Safety of <scp>BI</scp> 1358894 in patients with major depressive disorder: Results and learnings from a phase <scp>II</scp> randomized decentralized clinical trial
Clinical and Translational Science·2024· 4 citedOpen Access
A.9 Referenzwerte für Liquorparameter mit diagnostischer Relevanz
2024
C.2 Vom Liquorbefund zum klinischen Krankheitsbild
2024
C.1 Von der klinischen Diagnose zum Liquorbefund
2024
B.4 Supplementäre Marker
2024
C.3 Zur Befundbewertung in der Liquordiagnostik
2024
C.4 Aspekte, Kontroversen und Perspektiven der Liquorund neurochemischen Analytik
2024
Effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing using task-based fMRI in healthy subjects and patients with major depressive disorder — study protocol for a randomized clinical trial
Trials·2023· 3 citedOpen Access
Tryptophan catabolites and depression in the general population: results from the Gutenberg Health Study
BMC Psychiatry·2023· 7 citedOpen Access
Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809)
Translational Psychiatry·2022· 17 citedOpen Access
P712. Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of Bi 1569912 in Healthy Males: A Phase I Study
Biological Psychiatry·2022
The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation
Brain Behavior and Immunity·2021· 67 citedOpen Access
CSF Cells: Cell Count, Cytomorphology, Cytology, and Immunophenotyping
Neuromethods·2021
Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections
Cells·2020· 8 citedOpen Access
H31 Dysphagia in huntington´s disease – an observational study
2018· 2 cited
H33 The swallowing disorder in huntington’s disease (hd): an observational study – nutritional aspects
2018
Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial
PLoS ONE·2017· 54 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

G. Bernhard Landwehrmeyer(21), Hayrettin Tumani(19), Johannes Brettschneider(17), Albert C. Ludolph(14), Jan Kassubek(11), Michael Orth(9), Sarah J. Tabrizi(7), Hans‐Peter Müller(7), Markus Otto(6), Robert Christian Wolf(6), Georg Grön(6), Axel Petzold(5), Reiner Sprengelmeyer(5), Carsten Saft(4), Carolin Geitner(4), Vera Lehmensiek(4), Sarah Jesse(3), Josef Priller(3), Elmar H. Pinkhardt(3), Malte S. Depping(3)